{"version":"1.0","provider_name":"Laos Alliance Pharmaceutical Group","provider_url":"https:\/\/alliancepharmagroup.com\/lo","title":"LORANIB - Laos Alliance Pharmaceutical Group","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"LwApp4WCo0\"><a href=\"https:\/\/alliancepharmagroup.com\/lo\/\u0eaa\u0eb4\u0e99\u0e84\u0ec9\u0eb2\/loranib-2\/\">LORANIB<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/alliancepharmagroup.com\/lo\/\u0eaa\u0eb4\u0e99\u0e84\u0ec9\u0eb2\/loranib-2\/embed\/#?secret=LwApp4WCo0\" width=\"600\" height=\"338\" title=\"&#8220;LORANIB&#8221; &#8212; Laos Alliance Pharmaceutical Group\" data-secret=\"LwApp4WCo0\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/alliancepharmagroup.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>","thumbnail_url":"https:\/\/alliancepharmagroup.com\/wp-content\/uploads\/2024\/03\/Loranib.png","thumbnail_width":1280,"thumbnail_height":1280,"description":"COMPOSITION Lorlatinib \u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026100mg.  INDICATIONS LORANIB is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK) or ROS1 positive metastatic non-small cell lung cancer whose disease has progressed after: \u2022 Crizotinib and at least one other ALK inhibitor for metastatic disease. \u2022 Alectinib as the first line inhibitor therapy for metastatic disease. \u2022 Ceritinib as the first line ALK inhibitor therapy for metastatic disease.  PACKAGING: 30 tablets\/box.  Reg No: 10 L 0935\/22. Download Loranib Drug Registration Certificate ... Read More"}